NEW YORK

Regeneron Shares Hit New 10-Year High After Eye Drug Gets FDA Priority Review

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) touched a new 10-year high of $49.44 on Monday. The company said the U.S. Food and Drug Administration gave priority review status for its new investigational eye solution to treat neovascular form of age-related macular degeneration, or wet AMD, a disorder that causes vision loss due to abnormal growth of blood vessels.
More news

RIM PlayBook: A case study on how to miss opportunities?

PlayBook carries RIM's hopes that the device will vault it over Android and Apple's iPad, to position it as a tablet of choice. However, RIM's answer to Apple's iPad and Motorola Xoom and hundreds of other tablets comes in bit late.

Facebook Lawsuit: The Evidence For And Against

Facebook founder Mark Zuckerberg is facing a suit that could cost him billions if a judge finds that the documents presented so far are genuine. So the first question is whether they are or not.

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.